Evidence map›Paper›PMID 40646632›Full record

ArticleGenome biology2025

G-quadruplex structures regulate long-range transcriptional reprogramming to promote drug resistance in ovarian cancer cells.

Jenna Robinson, Gem Flint, Ian Garner, Silvia Galli, Thomas E Maher, Marina K Kuimova, Ramon Vilar, Iain A McNeish, Robert Brown, Hector Keun and 1 more

Abstract read
In one paragraph

Article in Genome biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. G-Quadruplexes: Structural Diversity and Emerging Roles in Biomolecular Condensation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jenna Robinson *Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, 82 Wood Lane, London, W12 0BZ, UK.
Gem Flint *Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, 82 Wood Lane, London, W12 0BZ, UK.
Ian GarnerDivision of Cancer, Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK.
Silvia GalliDepartment of Chemistry, Molecular Sciences Research Hub, Imperial College London, 82 Wood Lane, London, W12 0BZ, UK.
Thomas E MaherDepartment of Chemistry, Molecular Sciences Research Hub, Imperial College London, 82 Wood Lane, London, W12 0BZ, UK.
Marina K KuimovaDepartment of Chemistry, Molecular Sciences Research Hub, Imperial College London, 82 Wood Lane, London, W12 0BZ, UK.
Ramon VilarDepartment of Chemistry, Molecular Sciences Research Hub, Imperial College London, 82 Wood Lane, London, W12 0BZ, UK.
Iain A McNeishDivision of Cancer, Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK.
Robert BrownDivision of Cancer, Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK.
Hector KeunDivision of Cancer, Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK.
Marco Di AntonioDepartment of Chemistry, Molecular Sciences Research Hub, Imperial College London, 82 Wood Lane, London, W12 0BZ, UK. m.di-antonio@imperial.ac.uk.

Funding

Biotechnology and Biological Sciences Research Council BB/R011605/1Biotechnology and Biological Sciences Research Council BB/W016710/1Cancer Research UK CANTAC721\100021Engineering and Physical Sciences Research Council EP/S023518/1Lister Institute of Preventive Medicine Lister Prize 2022National Institute for Health and Care Research NF-SI-0514-10101
6 · The paper itself

Abstract

backgroundEpigenetic evolution is a common mechanism used by cancer cells to evade the therapeutic effects of drug treatment. In ovarian cancers, epigenetically driven resistance is thought to be responsible for many late-stage patient deaths. DNA secondary structures called G-quadruplexes (G4s) are emerging as potential epigenetic marks of relevance to cancer evolution, but their prevalence and distribution in ovarian cancer models have never been investigated before.

resultsHere, we describe the first investigation of the role of G4s in the epigenetic regulation of drug-resistant ovarian cancer cells. Through genome-wide mapping of G4s in paired drug-sensitive and drug-resistant cell lines, we find that increased G4 accumulation is associated with enhanced transcription of signalling pathways previously established to promote drug-resistant states, including genes involved in the epithelial to mesenchymal transition and WNT signalling. In contrast to previous studies, the expression-enhancing effects of G4s are not found at gene promoters, but intergenic and intronic regions, indicating that G4s can promote long-range transcriptional regulation in drug-resistant cells. Furthermore, we discover that clusters of G4s (super-G4s) are associated with particularly high levels of transcriptional enhancement that surpass the effects of super-enhancers, which act as well-established regulatory sites in many cancers. Finally, we demonstrate that targeting G4s with small molecules results in significant downregulation of pathways associated with drug resistance, resulting in resensitization of resistant cells to chemotherapy agents.

conclusionsThese findings indicate that G4 structures are critical for the epigenetic regulatory networks of drug-resistant cells and represent a promising target to treat drug-tolerant ovarian cancer.

Indexed as

Drug Resistance, NeoplasmG-QuadruplexesOvarian NeoplasmsTranscription, GeneticCell Line, TumorEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticHumansPromoter Regions, GeneticG-quadruplexesOvarian cancerResistanceTranscription

Identifiers

PMID40646632
PMCPMC12255116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.